Literature DB >> 31386368

HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.

Linah N Rusere1, Gordon J Lockbaum1, Sook-Kyung Lee2, Mina Henes1, Klajdi Kosovrasti1, Ean Spielvogel2, Ellen A Nalivaika1, Ronald Swanstrom2, Nese Kurt Yilmaz1, Celia A Schiffer1, Akbar Ali1.   

Abstract

A structure-guided design strategy was used to improve the resistance profile of HIV-1 protease inhibitors by optimizing hydrogen bonding and van der Waals interactions with the protease while staying within the substrate envelope. Stereoisomers of 4-(1-hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene moieties were explored as P2' ligands providing pairs of diastereoisomers epimeric at P2', which exhibited distinct potency profiles depending on the configuration of the hydroxyl group and size of the P1' group. While compounds with the 4-(1-hydroxyethyl)benzene P2' moiety maintained excellent antiviral potency against a panel of multidrug-resistant HIV-1 strains, analogues with the polar 4-(1,2-dihydroxyethyl)benzene moiety were less potent, and only the (R)-epimer incorporating a larger 2-ethylbutyl P1' group showed improved potency. Crystal structures of protease-inhibitor complexes revealed strong hydrogen bonding interactions of both (R)- and (S)-stereoisomers of the hydroxyethyl group with Asp30'. Notably, the (R)-dihydroxyethyl group was involved in a unique pattern of direct hydrogen bonding interactions with the backbone amides of Asp29' and Asp30'. The SAR data and analysis of crystal structures provide insights for optimizing these promising HIV-1 protease inhibitors.

Entities:  

Year:  2019        PMID: 31386368      PMCID: PMC6941148          DOI: 10.1021/acs.jmedchem.9b00838

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  49 in total

1.  Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

Authors:  John F Miller; C Webster Andrews; Michael Brieger; Eric S Furfine; Michael R Hale; Mary H Hanlon; Richard J Hazen; Istvan Kaldor; Ed W McLean; David Reynolds; Douglas M Sammond; Andrew Spaltenstein; Roger Tung; Elizabeth M Turner; Robert X Xu; Ronald G Sherrill
Journal:  Bioorg Med Chem Lett       Date:  2006-02-03       Impact factor: 2.823

2.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures.

Authors:  A T Brünger
Journal:  Nature       Date:  1992-01-30       Impact factor: 49.962

3.  HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.

Authors:  Michael D Altman; Akbar Ali; G S Kiran Kumar Reddy; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Sripriya Chellappan; Visvaldas Kairys; Miguel X Fernandes; Michael K Gilson; Celia A Schiffer; Tariq M Rana; Bruce Tidor
Journal:  J Am Chem Soc       Date:  2008-04-16       Impact factor: 15.419

4.  Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.

Authors:  Gordon J Lockbaum; Florian Leidner; Linah N Rusere; Mina Henes; Klajdi Kosovrasti; Gily S Nachum; Ellen A Nalivaika; Akbar Ali; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Infect Dis       Date:  2018-12-31       Impact factor: 5.084

5.  Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.

Authors:  Arun K Ghosh; Prasanth R Nyalapatla; Satish Kovela; Kalapala Venkateswara Rao; Margherita Brindisi; Heather L Osswald; Masayuki Amano; Manabu Aoki; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-05-15       Impact factor: 7.446

6.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

7.  Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.

Authors:  Djadé I Soumana; Nese Kurt Yilmaz; Akbar Ali; Kristina L Prachanronarong; Celia A Schiffer
Journal:  J Am Chem Soc       Date:  2016-09-02       Impact factor: 15.419

8.  Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions.

Authors:  J R Rosé; R Salto; C S Craik
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

9.  Molecular Basis for Drug Resistance in HIV-1 Protease.

Authors:  Akbar Ali; Rajintha M Bandaranayake; Yufeng Cai; Nancy M King; Madhavi Kolli; Seema Mittal; Jennifer F Murzycki; Madhavi N L Nalam; Ellen A Nalivaika; Ayşegül Özen; Moses M Prabu-Jeyabalan; Kelly Thayer; Celia A Schiffer
Journal:  Viruses       Date:  2010-11-12       Impact factor: 5.818

10.  Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.

Authors:  Ian W Windsor; Ronald T Raines
Journal:  Sci Rep       Date:  2015-08-11       Impact factor: 4.379

View more
  6 in total

1.  Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants.

Authors:  Mei Zhu; Yue Dou; Ling Ma; Biao Dong; Fan Zhang; Guoning Zhang; Juxian Wang; Jinming Zhou; Shan Cen; Yucheng Wang
Journal:  ACS Med Chem Lett       Date:  2020-03-31       Impact factor: 4.345

2.  Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.

Authors:  Linah N Rusere; Gordon J Lockbaum; Mina Henes; Sook-Kyung Lee; Ean Spielvogel; Desaboini Nageswara Rao; Klajdi Kosovrasti; Ellen A Nalivaika; Ronald Swanstrom; Nese Kurt Yilmaz; Celia A Schiffer; Akbar Ali
Journal:  J Med Chem       Date:  2020-08-03       Impact factor: 7.446

Review 3.  Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

Authors:  Ashley N Matthew; Florian Leidner; Gordon J Lockbaum; Mina Henes; Jacqueto Zephyr; Shurong Hou; Desaboini Nageswara Rao; Jennifer Timm; Linah N Rusere; Debra A Ragland; Janet L Paulsen; Kristina Prachanronarong; Djade I Soumana; Ellen A Nalivaika; Nese Kurt Yilmaz; Akbar Ali; Celia A Schiffer
Journal:  Chem Rev       Date:  2021-01-07       Impact factor: 60.622

4.  A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.

Authors:  Juan Wang; Boqiang Liang; Yiling Chen; Jasper Fuk-Woo Chan; Shuofeng Yuan; Hui Ye; Linlin Nie; Jiao Zhou; Yi Wu; Meixian Wu; Lina S Huang; Jing An; Arieh Warshel; Kwok-Yung Yuen; Aaron Ciechanover; Ziwei Huang; Yan Xu
Journal:  Eur J Med Chem       Date:  2021-02-10       Impact factor: 6.514

5.  Viral proteases: Structure, mechanism and inhibition.

Authors:  Jacqueto Zephyr; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  Enzymes       Date:  2021-11-17

6.  Inhibiting HTLV-1 Protease: A Viable Antiviral Target.

Authors:  Gordon J Lockbaum; Mina Henes; Nathaniel Talledge; Linah N Rusere; Klajdi Kosovrasti; Ellen A Nalivaika; Mohan Somasundaran; Akbar Ali; Louis M Mansky; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2021-02-23       Impact factor: 5.100

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.